Recipharm AB and Adroit Science AB have formed a strategic partnership. The companies plan to combine their expertise in formulation development, API development, chemical analysis and other areas to reduce time and cost of development while improving quality.
“I very much look forward to cooperation,” says Carl-Johan Lever, executive vice president, development & technology at Recipharm. “With Adroit development services assisting us, we will have a very competitive offering, which in a highly efficient manner helps our clients forward in their projects. We can offer our customers even better services, all the way from the molecular [level] to the finished product. ”
“Adroit Science and Recipharm already have collaborated successfully on a number of projects, and this formal partnership represents the next logical step in the mutual development of our strategic partnership,” according to Hans Gredeby, CEO of Adroit Science AB. “We are pleased to be working closely with a leading CDMO company such as Recipharm and expect that it will bring new opportunities in terms of global customer support.”